Systematic review and meta-analysis of MRAs in dialysis patients shows reduced nonfatal CVD events but elevated hyperkalemia and gynecomastia risks
New analysis shows dialysis drugs cut heart attacks but raise dangerous potassium risks
This systematic review and meta-analysis evaluated mineralocorticoid receptor antagonists (MRAs) in adults on maintenance dialysis. The pool…
A large review of dialysis patients found that specific heart drugs reduced nonfatal heart events but increased risks of severe potassium bu…
LP-184 Alone and With Spironolactone in Recurrent Glioblastoma: Phase 1a Results
New drug combo may help brain cancer patients who have run out of options
This Phase 1a trial in 63 patients (16 with glioblastoma) found LP-184 was well tolerated but with more transaminitis and thrombocytopenia i…
A new drug combination could help brain cancer patients by making their current medicine work much harder inside the tumor.
Spironolactone reduces cardiovascular events in HFpEF patients with increased LV mass or left atrial volume.
Spironolactone Saves Lives in Specific Heart Failure Types
This post hoc analysis of the TOPCAT randomized controlled trial evaluated spironolactone in 757 participants with heart failure with preser…
Spironolactone cuts death risk for heart failure patients with enlarged heart chambers, proving that heart size matters just as much as pump…